Cargando…

Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis

Objective: To investigate whether neoadjuvant chemotherapy (NACT) confers superior outcomes compared to primary debulking surgery (PDS) in patients with stage III and IV epithelial ovarian, tubal or peritoneal cancer as well as in patients with high tumour load. Methods: We searched the electronic d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tzanis, Alexander A., Iavazzo, Christos, Hadjivasilis, Alexandros, Tsouvali, Hara, Antoniou, George Α., Antoniou, Stavros A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756845/ https://www.ncbi.nlm.nih.gov/pubmed/36531160 http://dx.doi.org/10.3389/or.2022.10605

Ejemplares similares

Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
por: Menczer, Joseph, et al.
Publicado: (2011)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer
por: Tate, Shinichi, et al.
Publicado: (2019)

A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV
por: Dai-yuan, Ma, et al.
Publicado: (2013)

Safety and feasibility of robotic surgery in selected ovarian cancer patients undergoing interval debulking surgery
por: Iavazzo, Christos, et al.
Publicado: (2020)

Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
por: de Jong, Diederick, et al.
Publicado: (2023)

Secondary debulking for ovarian carcinoma relapse: The R-R dilemma – is the prognosis different for residual or recurrent disease?
por: Spiliotis, John D., et al.
Publicado: (2019)

Endometriosis III and IV as a risk factor for tubal obstruction in infertile women
por: Approbato, Fabiana C, et al.
Publicado: (2019)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
por: Tsoi, Tung Tung, et al.
Publicado: (2020)

The Diagnosis and Treatment of Acute Tubal Peritonitis
por: Struthers, J. W.
Publicado: (1922)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2020)

Impact of the Time Interval from Neoadjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and Peritoneal Cancer Patients
por: Chen, Ming, et al.
Publicado: (2018)

Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
por: Iura, Ayaka, et al.
Publicado: (2018)

Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer
por: Jiang, Yinan, et al.
Publicado: (2021)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

Clinical Outcome of a FIGO Stage IV Gestational Choriocarcinoma
por: Milenković, Vera, et al.
Publicado: (2013)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer
por: Métairie, Marie, et al.
Publicado: (2023)

Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis
por: Chang, Yen-Hou, et al.
Publicado: (2016)

Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
por: Vandenput, I, et al.
Publicado: (2009)

LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions
por: Schmoeckel, Elisa, et al.
Publicado: (2017)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team
por: Tozzi, Roberto, et al.
Publicado: (2021)

Tubal Distension and Stricture: A Cause of Intra-Peritoneal Hæmorrhage
por: Stevenson, E. Sinclair
Publicado: (1888)

Tubal Distension and Stricture: A Cause of Intra-Peritoneal Hæmorrhage
por: Stevenson, E. Sinclair
Publicado: (1888)

A Polymorphism Associated with Depressive Disorders Differentially Regulates Brain Derived Neurotrophic Factor Promoter IV Activity
por: Hing, Benjamin, et al.
Publicado: (2012)

Application Effectiveness of Segment IV Portal Vein Reconstruction for Early Postoperative Liver Function Recovery in Split Liver Transplantation
por: Muhammad, Imran, et al.
Publicado: (2023)

(18)F-FDG-PET/CT-guided intensity-modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study
por: Dang, Ya-Zheng, et al.
Publicado: (2019)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

Endometriotic Peritoneal Defect Is a Risk Factor for Peritoneal Ectopic Pregnancy or Tubal Abortion Implant
por: Kwek, Lee Koon, et al.
Publicado: (2021)

The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
por: Juris, Aubrey, et al.
Publicado: (2021)

When There is No Guidance From the Guidelines: Renal Transplantation in Recipients With Class III Obesity
por: Gillespie, Hannah, et al.
Publicado: (2023)

Debulking Atherectomy in the Peripheral Arteries: Is There a Role and What is the Evidence?
por: Katsanos, Konstantinos, et al.
Publicado: (2017)

Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection
por: Park, Sehoon, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy
por: Kong, Tae-Wook, et al.
Publicado: (2014)

Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response
por: Xing, Ai-Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u83nb9lj3bndta7553usevkphb